DPP-4 inhibitors were associated with an increased risk of acute pancreatitis in direct meta-analysis (Peto odds ratio 1.72; 95% CI 1.18–2.53; Supplemental Material) and with an absolute risk difference of 0.1% (representing a number needed to harm (NNH) of 1066). This evidence concerns the gene DPP4 and acute pancreatitis.